United Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de United Therapeutics es Martine Rothblatt , nombrado en Jan 1996, tiene una permanencia de 28.83 años. compensación anual total es $16.96M, compuesta por 8.7% salario y 91.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.49% de las acciones de la empresa, por valor de $248.65M. La antigüedad media del equipo directivo y de la junta directiva es de 15.6 años y 22.2 años, respectivamente.
Información clave
Martine Rothblatt
Chief Executive Officer (CEO)
US$17.0m
Compensación total
| Porcentaje del salario del CEO | 8.7% |
| Permanencia del CEO | 28.8yrs |
| Participación del CEO | 1.5% |
| Permanencia media de la dirección | 15.6yrs |
| Promedio de permanencia en la Junta Directiva | 22.2yrs |
Actualizaciones recientes de la dirección
Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Compensación vs. Mercado: La compensación total de Martine($USD16.96M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD12.66M).
Compensación vs. Ingresos: La compensación de Martine ha aumentado más de un 20% en el último año.
CEO
Martine Rothblatt (69 yo)
28.8yrs
Permanencia
US$16,958,057
Compensación
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 248.7m | |
| President & COO | 8.4yrs | US$9.81m | 0.0058% $ 960.6k | |
| CFO & Treasurer | 11.8yrs | US$6.05m | 0.018% $ 3.0m | |
| Executive VP | 28.8yrs | US$5.15m | 0.082% $ 13.7m | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Associate Vice President of Human Resources | no data | sin datos | sin datos | |
| Senior Vice President of Strategic Operations & Logistics | no data | sin datos | sin datos | |
| Executive VP of Technical Operations | 15.6yrs | sin datos | sin datos | |
| Executive Vice President of Product Development & Xenotransplantation | no data | sin datos | sin datos | |
| Senior VP & Chief Medical Officer | no data | sin datos | sin datos |
15.6yrs
Permanencia media
56yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de UTHR es experimentado (15.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 248.7m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 22.8yrs | US$457.60k | 0.027% $ 4.5m | |
| Independent Director & Member of the Scientific Advisory Board | 22.2yrs | US$471.54k | 0.029% $ 4.9m | |
| Independent Director & Member of the Scientific Advisory Board | 22.8yrs | US$456.54k | 0.0039% $ 652.6k | |
| Independent Vice Chairman & Lead Independent Director | 22.1yrs | US$532.60k | 0.0045% $ 745.8k | |
| Independent Director | 21.3yrs | US$481.54k | 0.0082% $ 1.4m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 22.8yrs | US$456.54k | 0.050% $ 8.4m | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 9.4yrs | US$488.66k | 0.013% $ 2.1m | |
| Independent Director | 15.6yrs | US$513.66k | 0.039% $ 6.5m |
22.2yrs
Permanencia media
76yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de UTHR son experimentados ( 22.2 años antigüedad media).